维普中文期刊产品整合服务
255篇 您的检索式:作者名="Willets"
    题名 作者 年代 出处 被引量
1Plasmon point spread functions: How do we model plasmon-mediated emission processes?显示文摘Katherine A. Willets 2014Frontiers of physics2014,9,1:3
2A prospective study of dietary glyeemic load, carbohydrate intake, and risk of coronary heart disease in US women 显示文摘Liu S Willet WC Stampfer MJ 2000Am J Clin Nutr2000,71,:1
3Capillary bridges between two spherical bodies显示文摘Willet C D Adams M J Johnson S A etal 2000Langmuir2000,16,24:1
4Current therapy of bladder cancer显示文摘Willet F Whitemore JR 1990J Occup Med1990,32,7:1
5Time course of changes in lung mechanics following etal steroid treatment显示文摘Lanteri CJ Willet KE Kano S 1994Am J Respir Crit Care Med1994,150,3:1
6Visualizing the temporal effects of vasoconstrictors on PKC translocation and Ca2+ signaling in single resistance arterial smooth muscle cells 显示文摘Nelson CP Willets JM Davies NW 2008Am J Physiol2008,295,6:1
7Failture of tibial plateau fracture显示文摘ALIA M El-SHSFIE M WILLET K M 2002J Orthop Trauma2002,16,5:1
8Localized surface plasnon resonance spectroscopy and sensing 显示文摘Willets K A Van Duyne R P 2007Annual Review of Physical Chemistry2007,58,:1
9A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in elderly 显示文摘Gaziano J Manson J Brance L Colditz G Willet W Buring J 1995Annals of Epidemiology1995,5,4:1
10Ectopic pregnancy is associated with high anandamide levels and aberrant expression of FAAH and CB 1 in fallopian tubes显示文摘Gebeh AK Willets JM Marczylo EL 2012J Clin Endocrinol Metab2012,97,8:1
11EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxy-genation显示文摘Du G Willet K Mouithys MA 1999Free Radic Biol Med1999,27,56:1
12Intake of fat,meat and fiber in relation to risk of colon cancer in men显示文摘Giovannucci E Rimm E B Stampfer M J Colditz G A Ascherio A Willet W C 1994Cancer Research1994,54,:1
13Selection fac-tors for local excision or abdominoperineal resection of early stage rectal cancer显示文摘Willet CG Compton CC Shellito PC 1994Cancer1994,73,11:1
14A prospective study of dietary glycemic loadl carbohydrate intake, and risk of coronary heart disease in US women显示文摘Liu S Willet W C Stampfer M J 2000Am J Clin Nutr2000,71,:1
15Pleural effusion in breast cancer: a review of the Nottingham experience显示文摘Banerjee AK Willets I Robertson JF 1994Eur J Surg Oncol1994,20,1:1
16The limitations of term co-occurrence data for query expansion in document retrieval systems 显示文摘PEAT H J WILLET P 1991Journal of American Society for Information Science1991,42,5:1
17Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs 显示文摘Willet KE Jobe AH Ikegami M Newnham J Brennan S Sly PD 2000Pediatr Res2000,48,6:1
18The grain/bed collision in sand transport by wind 显示文摘McEwan I K Willets B B Rice M A 1992Sedimentology1992,39,:1
19Guidelines for healthy weight显示文摘Willet WC Dietz WH Colditz GA 0,,:1
20United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment显示文摘AIM: To assess advanced neuroendocrine tumor (NET) treatment patterns and resource utilization by tumor progression stage and tumor site in the United States. METHODS: United States Physicians meeting eligibility criteria were provided with online data extraction forms to collect patient chart data on recent NET patients. Resource utilization and treatment pattern data were collected over a baseline period (after diagnosis and before tumor progression), as well as initial and secondary progression periods, with progression defined according to measureable radiographic evidence of tumor progression. Resource categories used in the analysis include: Treatments (e.g. , surgery, chemotherapy, radiotherapy, targeted therapies), hospitalizations and physician visits, diagnostic tests (biomarkers, imaging, laboratory tests). Comparisons between categories of resource utilization and tumor progression status were examined using univariate (by tumor site) and multivariate analyses (across all tumor sites). RESULTS: Fifty-five physicians were included in the study and completed online data extraction forms using the charts of 110 patients. The physician sample showed a relatively even distribution for those affiliated with academic versus community hospitals (46% vs 55%). Forty (36.3%) patients were reported to have pancreatic NET (pNET), while 70 (63.6%) patients had gastrointestinal tract (GI)/Lung as the primary NET site. Univariate analysis showed the proportion of patients hospitalized increased from 32.7% during baseline to 42.1% in the progression stages. While surgeries were performed at similar proportions overall at baseline and progression, pNET patients, were more likely than GI/Lung NET patients to have undergone surgery during the baseline (33.3% vs 25.0%) and any progression periods (26.7% vs 23.4%). While peptide-receptor radionuclide and targeted therapy utilization was low across NET types and tumor stages, GI/Lung types exhibited greater utilization of these technologies compared to pNET. Chemotherapy utilization was also greater among GI/Lung types. Multivariate analysis results demonstrated that patients in first progression period were over 3 times more likely to receive chemotherapy when compared to baseline (odds ratio: 3.31; 95%CI: 1.46-7.48, P=0.0041). Further, progression was associated with a greater likelihood of having a study physician visit [relative risk (RR): 1.54; 95%CI: 1.10-2.17, P=0.0117], and an increased frequency of other physician visits (RR: 1.84; 95%CI: 1.10-3.10, P=0.0211). CONCLUSION: Resource utilization in advanced NET in the United States is significant overall and data suggests progression has an impact on resource utilization regardless of NET tumor site.Jonathan Strosberg Roman Casciano Lee Stern Rohan Parikh Maruit Chulikavit Jacob Willet Zhimei Liu Xufang Wang Krzysztof J Grzegorzewski 2013World Journal of Gastroenterology2013,19,15:1
返回顶部 每页显示:
共13页 首页 上一页 第1页 下一页 末页 /13 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费